These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6379618)

  • 1. [Effect of bezafibrate on disorders of lipid metabolism].
    Stryjek-Kamińska D; Ilińska-Debniak K; Bartosiewicz W; Szczepanik Z
    Pol Tyg Lek; 1983 Dec; 38(50):1567-71. PubMed ID: 6379618
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of bezafibrate therapy on serum and lipoprotein lipids].
    Romics L; Németh Csóka M; Szám I; Pados G; Karádi I; Köszegi G; Kusztos R
    Orv Hetil; 1986 Oct; 127(40):2425-8, 2431. PubMed ID: 3537905
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes in the concentration and composition of lipids and lipoproteins in primary hyperlipoproteinemia during treatment with bezafibrate.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(8):1185-90. PubMed ID: 6685498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of apoproteins A and B, lipoproteins and plasma lipids during treatment with bezafibrate in various forms of hyperlipoproteinemia].
    Saitta A; Bonaiuto M; Lanzafame F; Mileto A; Pernice F; Cinquegrani M; Mazza G; Micali G; Pangallo A; Fodale P
    Clin Ter; 1988 Mar; 124(5):373-81. PubMed ID: 2974348
    [No Abstract]   [Full Text] [Related]  

  • 7. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sulfinpyrazone and lipoproteins: absence of effects on serum lipids in hyperlipoproteinemias of types II and IV].
    Sommariva D; Scotti L; Baroni L; Beggi P; Fasoli A
    Clin Ter; 1980 Mar; 92(6):649-55. PubMed ID: 7460493
    [No Abstract]   [Full Text] [Related]  

  • 9. [Comparative studies on the cholesterol and triglyceride-lowering effect of alpha-methylthyroxine (Skleronorm) and clofibrate (Regelan) in hyperlipoproteinemias of type IIa/b and IV].
    Jantke J; Schwartzkopff W; Zschiedrich M
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():392-5. PubMed ID: 206057
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypolipidemic effects of bezafibrate: studies in Italy.
    Postiglione A; Riccardi G; Saldalamacchia G
    Monogr Atheroscler; 1986; 14():198-202. PubMed ID: 3526125
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hypolipidemic effect of cholestyramine in patients affected by type II hyperlipoproteinemia].
    Sauvanet JP; Drouin P; Mejean L; Lambert D; Debry G
    Therapie; 1978; 33(5):615-22. PubMed ID: 217121
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapy of primary hyperlipoproteinemia types IIa, IIb and IV using beta pyridylcarbinol Study on three phases under ambulatory conditions].
    Klemens UH; von Löwis P
    Dtsch Med Wochenschr; 1973 Jun; 98(24):1197-202. PubMed ID: 4350685
    [No Abstract]   [Full Text] [Related]  

  • 13. [D-thyroxin in the therapy of type IIa and IIb hyperlipoproteinemias].
    Hempel RD; Müller G; Burchardt U
    Z Gesamte Inn Med; 1977 Jun; 32(11):suppl 175-6. PubMed ID: 201111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does hypolipidemic therapy prevent coronary heart disease?
    Rifkind BM; Levy RI
    Cardiovasc Clin; 1974; 6(2):1-8. PubMed ID: 4374303
    [No Abstract]   [Full Text] [Related]  

  • 15. [Antilipemic effect of bezafibrate in patients with hyperlipoproteinemia type IV].
    Chwistecki K; Mrukowicz M; Kopel E
    Wiad Lek; 1985 Apr; 38(7):490-4. PubMed ID: 4013323
    [No Abstract]   [Full Text] [Related]  

  • 16. Diagnosis and treatment of Type II and Type IV hyperlipoproteinemia in the office practice setting.
    Millett F; Sielski J; Stoll H; Alston N; Gail S
    PA J; 1976; 6(2):54-9. PubMed ID: 10235781
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lipid-lowering effect of etofibrate, bezafibrate and xanthinol nicotinate in patients with hyperlipoproteinemias].
    Machalke K; Djaja S; Richter E
    Ther Ggw; 1982 May; 121(5):301-11. PubMed ID: 6953613
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effectiveness of bezafibrate in ambulatory treatment of hyperlipidemia].
    Bartnikowska E; Michajlik A; Wegrzyn B
    Pol Tyg Lek; 1983 Sep; 38(39):1219-21. PubMed ID: 6371736
    [No Abstract]   [Full Text] [Related]  

  • 19. [Arteriosclerosis. III. Laboratory diagnosis of dyslipoproteinemia].
    Nowicka G; Kłosiewicz-Latoszek L
    Wiad Lek; 1985 Aug; 38(16):1179-84. PubMed ID: 4082589
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of bezafibrate on serum lipid, lipoprotein and apoprotein B levels in patients with type II and IV hyperlipoproteinemia].
    Sznajderman M
    Pol Arch Med Wewn; 1983; 70(5-6):259-69. PubMed ID: 6677890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.